Scleroderma Skin: How Is Treatment Best Guided by Data and Implemented in Clinical Practice?

Madelon C Vonk; Shervin Assassi; Anna-Maria Hoffmann-Vold

doi:10.1016/j.rdc.2023.01.003

Scleroderma Skin: How Is Treatment Best Guided by Data and Implemented in Clinical Practice?

Rheum Dis Clin North Am. 2023 May;49(2):249-262. doi: 10.1016/j.rdc.2023.01.003.

Authors

Madelon C Vonk¹, Shervin Assassi², Anna-Maria Hoffmann-Vold³

Affiliations

¹ Department of Rheumatology, Radboud University Nijmegen Medical Centre, Huispost 667, PO Box 9101, Nijmegen 6500HB, the Netherlands. Electronic address: Madelon.Vonk@Radboudumc.nl.
² Division of Rheumatology, The University of Texas Health Science Center at Houston, 6431 Fannin, Houston, TX, USA.
³ Department of Rheumatology, Oslo University Hospital - Rikshospitalet, Pb 4950, Nydalen, Oslo 0424, Norway.

PMID: 37028833
DOI: 10.1016/j.rdc.2023.01.003

Abstract

As skin involvement is the hall mark of systemic sclerosis (SSc) and changes of skin involvement have shown to correlate with internal organ involvement, assessing the extend of skin involvement is key. Although the modified Rodnan skin score is a validated tool used to evaluate the skin in SSc, it has its drawbacks. Novel imagine methods are promising but should be further evaluated. As for molecule markers for skin progression there are conflicting data on the predictive significance of baseline SSc skin gene expression profiles, but immune cell type signature in SSc skin correlates with progression.

Keywords: Biomarkers; Modified Rodnan skin score; Response to treatment; Skin involvement; Skin severity; Systemic sclerosis.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
Humans
Scleroderma, Systemic* / therapy
Skin / metabolism

Substances

Biomarkers